• depression is the most common mood disorder in patients with cerebrovascular disease (30-60% of patients with CVD)
    • depression occurs after both ischemic and hemorrhagic stroke
    • PSD can develop at any time after a stroke
      • the risk of PSD is highest during the first 3 months
      • the risk remains elevated for up to two years post-stroke or longer
    • the variability in the reported incidence of PSD (20-70%) is due to several factors
      • patient selection
      • timing of assessment
      • diagnostic criteria used
      • diagnosis of depression may be complicated by fatigue, aphasia, etc.
  • PSD negatively impacts stroke recovery
    • it can lead to poorer functional outcomes, decreased quality of life, and increased mortality
    • patients with PSD may have slower recovery, poorer rehabilitation outcomes, a higher level of dependency, and an increased risk of recurrent CVD [Sibolt, 2013]
  • PSD is also associated with more severe cognitive impairment  [Kauhanen, 1999]
  • PSD is often unrecognized and untreated
    • depression is often perceived as a natural reaction to stroke and not as a disease
    • diagnosis of PSD is also complicated by overlapping physical symptoms of stroke and depression, cognitive impairment, and communication difficulties
    • routine screening using standardized questionnaires is recommended (AHA/ASA 2019 I/B-NR)
  • other mood disorders may be observed (alongside depression or in isolation):
    • apathy (25-50%)
    • anxiety (25-50%)

Understanding PSD is crucial for healthcare providers to recognize the risk factors, implement appropriate screening measures, and provide timely and effective treatment to improve outcomes in stroke survivors. Regular monitoring and supportive care, along with interdisciplinary approaches involving neurology, psychiatry, psychology, and rehabilitation services, are key components in managing PSD.

Differential diagnosis of pseudodementia in depression

  • depression often leads to cognitive decline and can be mistaken for dementia, condition known as pseudodementia
  • specific characteristics in the clinical presentation and course of the disease can serve as a guide to distinguish between the two disorders (see the table)
  • improvement in cognitive function following successful treatment of depression confirms the correct diagnosis

Pathogenesis

The pathogenesis of post-stroke depression is multifactorial and not fully understood, involving a complex interplay of biological, psychological, and social factors

  • psychological concept
    • assumes that depression occurs as a reaction to one’s illness, often associated with disability
    • this concept is supported by the occurrence of similar depression in cardiovascular diseases or cancer.
  • organic concept
    • a consequence of damage to brain areas involved in mood regulation and the influence of stroke on various neurotransmitters (especially serotonin and catecholamines)
      • some authors suggest that lesions in the left hemisphere, especially in the prefrontal area, play a more important role, while other authors deny the existence of a clinical-topographic correlation
    • stroke also induces an inflammatory response in the brain, which has been associated with the development of depression
    • the organic concept is supported by the fact that no clear relationship has been found between the severity of neurological deficit and the presence of depression, and that depression occurs even in patients with clinically silent ischemic lesions (detected by CT or MRI)
  • other contributing factors
    • certain medications used in stroke recovery may have depressive side effects
    • stresses related to personal life, work, financial concerns, limited social support, and increased social isolation after a stroke may also contribute depression

This complexity necessitates a multidisciplinary approach to effectively manage PSD, including medical, psychological, and social support interventions. Regular screening and early identification of depression in stroke survivors are critical for timely and appropriate intervention.

Factors increasing the risk of PSD:
  • history of depression
  • personality features
  • poor social background, social isolation
  • severe stroke (high mRS)
  • left hemispheric stroke location
  • cognitive impairment
  • lacrimosity and apathy in the acute stage

Diagnostic evaluation

  • the main symptoms of depression according to the ICD 10 classification are summarized in the table below
  • symptoms should not result from direct exposure to a substance (medication, drugs) or a medical condition (e.g., hypothyroidism) and should not be attributed to grief (e.g., loss of a loved one, etc.)
  • diagnosis is based on a structured interview and scales that allow quantitative assessment of depression and tracking of its course over time
  • if the diagnosis is unclear, a trial of antidepressants is recommended

Management

  • only a minority of PSD patients achieve spontaneous remission even without treatment
  • early and effective treatment of PSD can have a significant positive impact on the course of recovery, with SSRIs reducing depression and anxiety and improving neurological deficit   [Mead, 2012]
  • it is not yet known whether stroke patients could benefit from routine temporary use of SSRIs
  • the mainstay of treatment includes SSRIs + psychotherapy and early intensive rehabilitation  [Andersen,1994]   [Wiart, 200]   [Rasmussen,2003]
    • SSRIs inhibit the reuptake of serotonin into nerve endings, thereby increasing the amount of serotonin in the synaptic cleft, which acts on postsynaptic receptors
    • SSRI have little or no affinity for cholinergic, histaminergic, and various adrenergic and dopaminergic receptors
    • antidepressant effects can be expected after 10-20 days of treatment; if the patient does not respond after 3 weeks, consider increasing the dose
    • treatment should be continued for at least 6 months
    • concomitant use of MAOIs is contraindicated

Selective serotonin reuptake inhibitors (SSRI)

Do not administer SSRIs to patients treated with monoamine oxidase inhibitors (MAOIs) ⇒  risk of serotonin syndrome

  • do not administer within14 days after discontinuation of an irreversible MAOI or for the specified period after discontinuation of a reversible MAOI (RIMA), as stated in the recommendations
  • MAOIs should not be started within 7 days after discontinuation of an SSRI
Citalopram

citalopram (DESYREL, TRAZODONE, OLEPTRO)

tablet: 10 – 20 – 40 mg

 

  • initial dose: 10 mg once daily
  • according to individual patient response, increase the dose up to 40 mg/d
  • in patients > 65 years of age use dose of 10-20 mg daily
  • do not stop treatment abruptly – reduce the dose over 1-2 weeks to avoid the risk of withdrawal symptoms
    • if difficulties occur in association with dose reduction or discontinuation, it is recommended to return to the original dosage
    • subsequently, continue to reduce the dose at a much slower rate
  • citalopram enhances serotonergic transmission through the inhibition of serotonin (5-HT) reuptake in the central nervous system (CNS)
  • it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors
  • monoamine oxidase inhibitors (IMAOs), including selegiline, at doses greater than 10 mg per day
    • citalopram should not be given for 14 days after discontinuation of an irreversible IMAO or for a specified period after discontinuation of a reversible IMAO (RIMA)
    • IMAOs should not be started for 7 days after discontinuation of citalopram
  • keep at least a 1-day interval between discontinuation of moclobemide and initiation of citalopram
  • in patients with acquired QT interval prolongation or congenital long QT interval syndrome, the concomitant use of citalopram with drugs known to prolong the QT interval is contraindicated
  • nausea, dry mouth, diarrhea, constipation, and vomiting
  • dizziness, headache, somnolence (sleepiness), and insomnia
  • increased anxiety, agitation, and nervousness, especially early in treatment
  • general feelings of tiredness or weakness
  • QT interval prolongation
  • serotonin syndrome – a potentially life-threatening condition caused by excessive serotonergic activity, characterized by symptoms like agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity, and fever
  • suicidal thoughts and behavior, particularly noted in children, adolescents, and young adults
  • serotonin syndrome is a serious and potentially life-threatening condition that can occur due to drug interactions leading to an excess of serotonin in the central nervous system. Here are some key drug interactions that can increase the risk of serotonin syndrome:
    • other SSRIs or SNRIs
    • monoamine oxidase inhibitors (MAOIs)
      • combining MAOIs with SSRIs, SNRIs, tricyclic antidepressants, or other serotonergic agents can lead to a dangerous increase in serotonin levels
    • tricyclic antidepressants (TCAs)
    • tramadol and fentanyl
    • triptans
    • ondansetron
    • drugs, such as MDMA (ecstasy), LSD, and cocaine
Escitalopram

escitalopram (CIPRALEX, LEXAPRO)

tablet: 5 – 10 – 20 mg

 

  • the usual dose is 10 mg once daily
    • the initial dose of 5 mg  is advised for elderly patients
  • depending on the individual patient’s response, the dose may be increased to a maximum of 20 mg per day (10 mg in elderly patients)
  • the antidepressant effect usually sets in after 2-4 weeks of treatment
  • after the symptoms have subsided, it is necessary to continue treatment for at least 6 months
  • escitalopram enhances serotonergic transmission through the inhibition of serotonin (5-HT) reuptake in the central nervous system (CNS)
  • it has minimal effect on other neurotransmitters
  • treatment with non-selective irreversible monoamine oxidase inhibitors (MAO inhibitors)
    • escitalopram should not be given for 14 days after discontinuation of an irreversible IMAO or a specified period after discontinuation of a reversible IMAO (RIMA)
    • IMAOs should not be started for 7 days after discontinuation of escitalopram
  • combination of escitalopram and reversible MAO-A inhibitors (e.g., moclobemide) or reversible non-selective MAO inhibitor linezolid
  • patients with known QT interval prolongation or with congenital long QT interval syndrome
  • use of escitalopram with medicinal products known to prolong the QT interval
  • pregnancy and breastfeeding (the safety of escitalopram during pregnancy and breastfeeding is not fully established)
  • bipolar disorder – use with caution in patients with bipolar disorder, as SSRIs can induce mania or hypomania
  • serotonin syndrome
  • headache, nausea
  • allergic reaction
  • hyponatremia – especially in elderly patients, leading to symptoms like headache, confusion, slurred speech
  • QT interval prolongation
  • serotonin syndrome – a potentially life-threatening condition caused by excessive serotonergic activity, characterized by symptoms like agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity, and fever
  • suicidal thoughts and behavior particularly noted in children, adolescents, and young adults
  • mania/hypomania activation in people with bipolar disorder or those predisposed to these conditions
  • sexual dysfunction (decreased libido, delayed ejaculation, and anorgasmia)
Fluoxetine
Sertraline

Serotonin antagonist and reuptake inhibitor (SARI)

Selective serotonin/norepinephrine reuptake inhibitors (SNRI)

Selective catecholamine and dopamine reuptake inhibitor (DNRI)

Multimodal antidepressants

Related Content

You cannot copy content of this page

Send this to a friend
Hi,
you may find this topic useful:

Poststroke depression
link: https://www.stroke-manual.com/poststroke-depression-psd/